Publication | Closed Access

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum–taxane based therapy—A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)☆

OncologyEndocrine-related CancerMedicineCancer ManagementGynecologyPharmacotherapyCancer TreatmentPharmacologyOvarian Cancer RefractoryGynecology OncologyMolecular OncologyAgo-ovar 2.6Ovarian Cancer